SUTRO BIOPHARMA, INC. (STRO) Net margin 2016–2025
SUTRO BIOPHARMA, INC. (STRO) net profit margin by fiscal year — reported net income divided by reported revenue.
-186.5%FY2025 · since FY2016: 2.8% → -186.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -186.5% | +180.2 pp |
| FY2024 | -366.6% | -297.2 pp |
| FY2023 | -69.5% | +106.4 pp |
| FY2022 | -175.9% | -5.3 pp |
| FY2021 | -170.6% | -95.4 pp |
| FY2020 | -75.2% | +203.7 pp |
| FY2019 | -278.9% | -187.0 pp |
| FY2018 | -91.9% | -53.9 pp |
| FY2017 | -38.1% | -40.9 pp |
| FY2016 | 2.8% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More STRO financial trends
STRO RevenueSTRO Net incomeSTRO Gross profitSTRO Gross marginSTRO Operating incomeSTRO Operating marginSTRO Operating cash flowSTRO Free cash flowSTRO Capital expendituresSTRO Return on equitySTRO Stock buybacksSTRO Dividends paidSTRO Total assetsSTRO Total liabilitiesSTRO Shareholders’ equitySTRO overview →